文献速递骨质疏松与钙磷/甲状旁腺

低磷酸酯酶症患者的循环微小RNA:HPP中首次微小RNA分析的结果

Circulating Micro-RNAs in Patients With Hypophosphatasia: Results of the First Micro-RNA Analysis in HPP.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

研究对24例成人低磷酸酯酶症(HPP)患者和24例健康对照进行小RNA测序,发现84个微小RNA(miRNA)表达显著不同,并验证了6个miRNA;37个miRNA与碱性磷酸酶水平相关,仅3个与磷酸吡哆醛相关,提示miRNA可能作为HPP多系统受累的生物标志物。

要点

  • 成人HPP患者与健康对照的年龄和性别可比,91%患者报告肌肉骨骼疼痛,64%有骨折史。
  • 小RNA测序发现84个miRNA在HPP与对照间表达显著不同(P<.05),验证了6个miRNA。
  • 37个miRNA与碱性磷酸酶水平相关,仅3个与磷酸吡哆醛相关。

核心结论

  • 这些发现突显了HPP多器官系统的深度受累,以及miRNA作为HPP对各系统影响的生物标志物的潜力。

研究设计与样本

  • 采用小RNA测序进行非靶向miRNA生物标志物发现,研究24例成人HPP患者(ALPL基因致病性变异、HPP相关临床症状、反复低碱性磷酸酶)和24例健康对照的细胞游离miRNA谱。

主要发现

  • 患者与对照年龄(47.9 ± 14.2 vs 45.9 ± 8.8岁,P = .980)和性别(女性55.5% vs 47.8%,P = 1.000)可比。
  • 91%患者报告肌肉骨骼疼痛,41%报告弥漫性神经系统症状,64%有骨折史。
  • 下一代测序分析中84个miRNA在HPP与对照间表达显著不同(P < .05)。
  • 选择14个miRNA(标准:P < .05,组织特异性指数 >0.7,log2倍数变化 >+0.8或<-0.8)用RT-定性PCR验证,验证了其中6个(P < .05;miR-122-3p、miR-140-5p、miR-143-3p、miR-155-5p、miR-451a、miR-92a-3p)。
  • 靶点预测和富集分析识别出与肌肉骨骼系统和中枢神经系统的关联;37个miRNA与碱性磷酸酶水平相关,仅3个与磷酸吡哆醛相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Adult hypophosphatasia (HPP) patients present with diffuse heterogenous symptoms often mimicking rheumatological diseases or osteoporosis and therefore accompanied by delayed diagnosis. The aim of this study was to identify circulating microRNAs (miRNAs) in adult HPP patients and to identify potential associations with clinical patients' characteristics. METHODS: We utilized untargeted miRNA biomarker discovery by small RNA-sequencing to investigate cell-free miRNA profiles in 24 adult HPP patients (pathogenic variant of the ALPL gene, HPP-related clinical symptoms, and repeatedly low alkaline phosphatase) and 24 healthy controls (CTRL). RESULTS: Patients and CTRL were comparable in age (47.9 ± 14.2 vs 45.9 ± 8.8 years, P = .980) and sex (55.5% vs 47.8% females, P = 1.000). In total, 91% of patients reported musculoskeletal pain, 41% diffuse neurological symptoms, and 64% history of fractures. In total, 84 miRNAs were significantly differently expressed between HPP and CTRL in next-generation sequencing analysis (P < .05). Of these, 14 miRNAs were selected (selection criteria: P < .05, tissue specificity index >0.7, log2 fold change >+0.8 or <-0.8) for validation using RT-qualitative PCR, which verified 6 of 14 selected miRNAs (P < .05; miR-122-3p, miR-140-5p, miR-143-3p, miR-155-5p, miR-451a, miR-92a-3p). Target prediction and enrichment analysis identified associations with the musculoskeletal system and the central nervous system. In total, 37 miRNAs correlated with alkaline phosphatase levels, but only 3 miRNAs with pyridoxal-5'-phosphate. CONCLUSION: These findings highlight a profound involvement of multiple organ systems and the potential of miRNAs as biomarkers for the effect of HPP on various systems. CLINICAL TRIALS NO: NCT04018287.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Haschka J, Messner Z, Feurstein J, et al. Circulating Micro-RNAs in Patients With Hypophosphatasia: Results of the First Micro-RNA Analysis in HPP. J Clin Endocrinol Metab. 2025. PMID: 39930630. doi:10.1210/clinem/dgaf080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。